Insider Selling: Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Chairman Sells $100,840.00 in Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Chairman Thomas Gad sold 4,000 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $25.21, for a total transaction of $100,840.00.

Thomas Gad also recently made the following trade(s):

  • On Monday, September 16th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $30.59, for a total transaction of $122,360.00.
  • On Tuesday, September 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $25.77, for a total transaction of $103,080.00.
  • On Monday, August 19th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $27.70, for a total transaction of $110,800.00.
  • On Monday, August 5th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $21.78, for a total transaction of $87,120.00.
  • On Monday, July 22nd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.54, for a total transaction of $90,160.00.

YMAB stock opened at $26.05 on Friday. Y-mAbs Therapeutics, Inc has a 52 week low of $15.17 and a 52 week high of $32.27. The company has a market cap of $901.17 million and a P/E ratio of -17.37. The company has a current ratio of 9.04, a quick ratio of 9.04 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $27.41 and its 200 day moving average price is $24.29.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.05). On average, equities research analysts expect that Y-mAbs Therapeutics, Inc will post -2.1 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Nuveen Asset Management LLC purchased a new stake in shares of Y-mAbs Therapeutics in the second quarter valued at about $1,827,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Y-mAbs Therapeutics by 16.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 748,351 shares of the company’s stock valued at $17,115,000 after purchasing an additional 108,054 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Y-mAbs Therapeutics in the second quarter valued at about $686,000. Cormorant Asset Management LP lifted its holdings in shares of Y-mAbs Therapeutics by 39.8% in the second quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock valued at $22,870,000 after purchasing an additional 284,518 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 72.0% in the second quarter. Vanguard Group Inc. now owns 489,582 shares of the company’s stock valued at $11,196,000 after purchasing an additional 205,021 shares in the last quarter. 32.06% of the stock is currently owned by institutional investors.

A number of research firms recently commented on YMAB. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 5th. Wedbush began coverage on shares of Y-mAbs Therapeutics in a report on Tuesday, September 3rd. They set an “outperform” rating and a $38.00 price objective on the stock. HC Wainwright set a $40.00 price objective on shares of Y-mAbs Therapeutics and gave the stock a “buy” rating in a report on Monday, August 26th. Finally, Cowen reissued a “buy” rating on shares of Y-mAbs Therapeutics in a report on Monday, July 1st. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Y-mAbs Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $32.50.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Further Reading: What are popular range trading strategies?

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.